249 related articles for article (PubMed ID: 32368049)
21. Nanovaccine based on a protein-delivering dendrimer for effective antigen cross-presentation and cancer immunotherapy.
Xu J; Wang H; Xu L; Chao Y; Wang C; Han X; Dong Z; Chang H; Peng R; Cheng Y; Liu Z
Biomaterials; 2019 Jul; 207():1-9. PubMed ID: 30947117
[TBL] [Abstract][Full Text] [Related]
22. Intracellular signaling pathway in dendritic cells and antigen transport pathway in vivo mediated by an OVA@DDAB/PLGA nano-vaccine.
Han S; Ma W; Jiang D; Sutherlin L; Zhang J; Lu Y; Huo N; Chen Z; Engle JW; Wang Y; Xu X; Kang L; Cai W; Wang L
J Nanobiotechnology; 2021 Nov; 19(1):394. PubMed ID: 34838057
[TBL] [Abstract][Full Text] [Related]
23. "Minimalist" Nanovaccine Constituted from Near Whole Antigen for Cancer Immunotherapy.
Wang K; Wen S; He L; Li A; Li Y; Dong H; Li W; Ren T; Shi D; Li Y
ACS Nano; 2018 Jul; 12(7):6398-6409. PubMed ID: 29927574
[TBL] [Abstract][Full Text] [Related]
24. The STING activator c-di-AMP exerts superior adjuvant properties than the formulation poly(I:C)/CpG after subcutaneous vaccination with soluble protein antigen or DEC-205-mediated antigen targeting to dendritic cells.
Volckmar J; Knop L; Stegemann-Koniszewski S; Schulze K; Ebensen T; Guzmán CA; Bruder D
Vaccine; 2019 Aug; 37(35):4963-4974. PubMed ID: 31320219
[TBL] [Abstract][Full Text] [Related]
25. Synergistic Glutathione Depletion and STING Activation to Potentiate Dendritic Cell Maturation and Cancer Vaccine Efficacy.
Liu J; Zhang Y; Yang B; Jia Y; Liu RT; Ding L; Shen Z; Chen X
Angew Chem Int Ed Engl; 2024 Mar; 63(10):e202318530. PubMed ID: 38196070
[TBL] [Abstract][Full Text] [Related]
26. A novel strategy utilizing ultrasound for antigen delivery in dendritic cell-based cancer immunotherapy.
Suzuki R; Oda Y; Utoguchi N; Namai E; Taira Y; Okada N; Kadowaki N; Kodama T; Tachibana K; Maruyama K
J Control Release; 2009 Feb; 133(3):198-205. PubMed ID: 19000727
[TBL] [Abstract][Full Text] [Related]
27. Nanoscale Coordination Polymer Based Nanovaccine for Tumor Immunotherapy.
Zhao H; Xu J; Li Y; Guan X; Han X; Xu Y; Zhou H; Peng R; Wang J; Liu Z
ACS Nano; 2019 Nov; 13(11):13127-13135. PubMed ID: 31710460
[TBL] [Abstract][Full Text] [Related]
28. Targeted Codelivery of an Antigen and Dual Agonists by Hybrid Nanoparticles for Enhanced Cancer Immunotherapy.
Zhang L; Wu S; Qin Y; Fan F; Zhang Z; Huang C; Ji W; Lu L; Wang C; Sun H; Leng X; Kong D; Zhu D
Nano Lett; 2019 Jul; 19(7):4237-4249. PubMed ID: 30868883
[TBL] [Abstract][Full Text] [Related]
29. Tumor immunotherapy using adenovirus vaccines in combination with intratumoral doses of CpG ODN.
Geary SM; Lemke CD; Lubaroff DM; Salem AK
Cancer Immunol Immunother; 2011 Sep; 60(9):1309-17. PubMed ID: 21626029
[TBL] [Abstract][Full Text] [Related]
30. Conjugation of ovalbumin to trimethyl chitosan improves immunogenicity of the antigen.
Slütter B; Soema PC; Ding Z; Verheul R; Hennink W; Jiskoot W
J Control Release; 2010 Apr; 143(2):207-14. PubMed ID: 20074597
[TBL] [Abstract][Full Text] [Related]
31. pH-Responsive nanoparticle vaccines for dual-delivery of antigens and immunostimulatory oligonucleotides.
Wilson JT; Keller S; Manganiello MJ; Cheng C; Lee CC; Opara C; Convertine A; Stayton PS
ACS Nano; 2013 May; 7(5):3912-25. PubMed ID: 23590591
[TBL] [Abstract][Full Text] [Related]
32. A Fluorinated Supramolecular Self-Assembled Peptide as Nanovaccine Adjuvant for Enhanced Cancer Vaccine Therapy.
Jia S; Ji S; Zhao J; Lv Y; Wang J; Sun D; Ding D
Small Methods; 2023 May; 7(5):e2201409. PubMed ID: 36802205
[TBL] [Abstract][Full Text] [Related]
33. Extending antigen release from particulate vaccines results in enhanced antitumor immune response.
Kapadia CH; Tian S; Perry JL; Sailer D; Christopher Luft J; DeSimone JM
J Control Release; 2018 Jan; 269():393-404. PubMed ID: 29146244
[TBL] [Abstract][Full Text] [Related]
34. An Immunological Approach to the Biocompatibility of Mesoporous SiO
Montes-Casado M; Sanvicente A; Casarrubios L; Feito MJ; Rojo JM; Vallet-Regí M; Arcos D; Portolés P; Portolés MT
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33167415
[TBL] [Abstract][Full Text] [Related]
35. Rational design of Polymeric Hybrid Micelles to Overcome Lymphatic and Intracellular Delivery Barriers in Cancer Immunotherapy.
Li H; Li Y; Wang X; Hou Y; Hong X; Gong T; Zhang Z; Sun X
Theranostics; 2017; 7(18):4383-4398. PubMed ID: 29158834
[TBL] [Abstract][Full Text] [Related]
36. A comparative study of the antigen-specific immune response induced by co-delivery of CpG ODN and antigen using fusion molecules or biodegradable microparticles.
Zhang XQ; Dahle CE; Weiner GJ; Salem AK
J Pharm Sci; 2007 Dec; 96(12):3283-92. PubMed ID: 17497736
[TBL] [Abstract][Full Text] [Related]
37. Polymer-Protein Nanovaccine Synthesized via Reactive Self-Assembly with Potential Application in Cancer Immunotherapy: Physicochemical and Biological Characterization In Vitro and In Vivo.
Zhang M; Chen W; Ju Y; Zhao H; Wang C
Macromol Rapid Commun; 2023 Dec; 44(23):e2300438. PubMed ID: 37708966
[TBL] [Abstract][Full Text] [Related]
38. Lymph Node-Targeting Nanovaccine through Antigen-CpG Self-Assembly Potentiates Cytotoxic T Cell Activation.
Xi X; Zhang L; Lu G; Gao X; Wei W; Ma G
J Immunol Res; 2018; 2018():3714960. PubMed ID: 30018987
[TBL] [Abstract][Full Text] [Related]
39. Cell-Penetrating Peptide Enhanced Antigen Presentation for Cancer Immunotherapy.
Wu H; Zhuang Q; Xu J; Xu L; Zhao Y; Wang C; Yang Z; Shen F; Liu Z; Peng R
Bioconjug Chem; 2019 Aug; 30(8):2115-2126. PubMed ID: 31339694
[TBL] [Abstract][Full Text] [Related]
40. CpG-DNA aided cross-presentation of soluble antigens by dendritic cells.
Maurer T; Heit A; Hochrein H; Ampenberger F; O'Keeffe M; Bauer S; Lipford GB; Vabulas RM; Wagner H
Eur J Immunol; 2002 Aug; 32(8):2356-64. PubMed ID: 12209649
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
